Nammi Therapeutics Overview
- Year Founded
-
2018
- Status
-
Private
- Employees
-
8
- Latest Deal Type
-
Series B
- Latest Deal Amount
-
$30M
- Investors
-
3
Nammi Therapeutics General Information
Description
Operator of an immunotherapy company intended to provide improved treatment of cancer. The company combines immune-modulating prodrugs into lipid nanoparticles for selective delivery to tumors as well as to fight cancer without the serious side effects associated with chemotherapy, enabling patients to receive efficient treatment and recover at a faster speed
Contact Information
Website
www.nammirx.comCorporate Office
- 10940 Wilshire Boulevard
- Suite 600
- Los Angeles, CA 90024
- United States
Corporate Office
- 10940 Wilshire Boulevard
- Suite 600
- Los Angeles, CA 90024
- United States
Nammi Therapeutics Timeline
Nammi Therapeutics Valuation & Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 6. Later Stage VC (Series B) | 01-Jul-2024 | $30M | Completed | Pre-Clinical Trials | ||
| 5. Later Stage VC (Series B1) | 03-Mar-2023 | Completed | Pre-Clinical Trials | |||
| 4. Grant | 15-Dec-2022 | Completed | Pre-Clinical Trials | |||
| 3. Early Stage VC (Series B) | 01-Jan-2020 | Completed | Pre-Clinical Trials | |||
| 2. Early Stage VC (Series A) | 01-Jan-2019 | $10M | $10M | Completed | Pre-Clinical Trials | |
| 1. Accelerator/Incubator | Completed | Pre-Clinical Trials |
Nammi Therapeutics Cap Table
| Stock | # of Shares Authorized |
Par Value | Dividend Rate (%) | Original Issue Price |
Liquidation | Liquidation Pref. Multiple |
Conversion Price | % Owned |
|---|---|---|---|---|---|---|---|---|
| Series B-1 | ||||||||
| Series B | ||||||||
| Series A | 12,500,000 | $0.000100 | $0.8 | $0.8 | 1x | $0.8 | 34.97% |
VC Exit Predictor
See how our proprietary methodology utilizes historical data sets to synthesize the likelihood of an acquisition, IPO, or no exit event. Get a detailed look at the calculations behind our predictions.
Nammi Therapeutics Patents
Nammi Therapeutics Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| WO-2026117686-A1 | Fusion protein composition(s) comprising masked type i interferons (ifnα and ifnβ) for use in the treatment of cancer and methods thereof | Pending | 27-Nov-2024 | ||
| US-12788819-B2 | Formulated and/or co-formulated liposome compositions containg tgfβ antagonist prodrugs useful in the treatment of cancer and methods thereof | Active | 10-Jul-2023 | ||
| AU-2023232077-A1 | Formulated and/or co-formulated lipid nanocarriers compositions containing toll-like receptor ("tlr") agonist prodrugs useful in the treatment of cancer and methods thereof | Pending | 10-Mar-2022 | ||
| EP-4489784-A1 | Formulated and/or co-formulated lipid nanocarriers compositions containing toll-like receptor ("tlr") agonist prodrugs useful in the treatment of cancer and methods thereof | Pending | 10-Mar-2022 | ||
| US-20240108732-A1 | Formulated and/or co-formulated lipid nanocarriers compositions containing toll-like receptor ("tlr") agonist prodrugs useful in the treatment of cancer and methods thereof | Pending | 10-Mar-2022 | A61K31/522 |
Nammi Therapeutics Signals
Nammi Therapeutics Investors (3)
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds |
|---|---|---|---|---|
| Myeloma Investment Fund | Not-For-Profit Venture Capital | Minority | ||
| California Institute for Regenerative Medicine | Government | |||
| Magnify | Accelerator/Incubator |
Nammi Therapeutics Acquisitions (1)
Nammi Therapeutics’s most recent deal was a Merger/Acquisition with Qwixel Therapeutics. The deal was made on 01-Jan-2021.
| Company Name | Deal Date | Deal Type | Deal Size | Industry | Lead Partner |
|---|---|---|---|---|---|
| Qwixel Therapeutics | 01-Jan-2021 | Merger/Acquisition | Drug Discovery |
Nammi Therapeutics FAQs
-
When was Nammi Therapeutics founded?
Nammi Therapeutics was founded in 2018.
-
Where is Nammi Therapeutics headquartered?
Nammi Therapeutics is headquartered in Los Angeles, CA.
-
What is the size of Nammi Therapeutics?
Nammi Therapeutics has 8 total employees.
-
What industry is Nammi Therapeutics in?
Nammi Therapeutics’s primary industry is Drug Discovery.
-
Is Nammi Therapeutics a private or public company?
Nammi Therapeutics is a Private company.
-
What is the current valuation of Nammi Therapeutics?
The current valuation of Nammi Therapeutics is .
-
What is Nammi Therapeutics’s current revenue?
The current revenue for Nammi Therapeutics is .
-
How much funding has Nammi Therapeutics raised over time?
Nammi Therapeutics has raised $66.5M.
-
Who are Nammi Therapeutics’s investors?
Myeloma Investment Fund, California Institute for Regenerative Medicine, and Magnify have invested in Nammi Therapeutics.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process